Minerva Neurosciences (NASDAQ:NERV) Stock Rating Lowered by Wall Street Zen

Minerva Neurosciences (NASDAQ:NERV) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

Several other equities research analysts have also weighed in on the company. HC Wainwright dropped their target price on Minerva Neurosciences from $5.00 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Minerva Neurosciences in a research report on Monday, December 29th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $4.00.

Minerva Neurosciences Trading Down 5.3%

Shares of NASDAQ NERV opened at $4.45 on Friday. The company has a market capitalization of $192.57 million, a price-to-earnings ratio of -2.41 and a beta of -0.28. Minerva Neurosciences has a twelve month low of $1.15 and a twelve month high of $12.46. The business has a 50 day simple moving average of $3.98 and a 200-day simple moving average of $2.92.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.01). As a group, equities analysts predict that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Apella Capital LLC increased its stake in Minerva Neurosciences, Inc (NASDAQ:NERV) by 87.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,314 shares of the biopharmaceutical company’s stock after purchasing an additional 18,375 shares during the quarter. Apella Capital LLC’s holdings in Minerva Neurosciences were worth $83,000 at the end of the most recent quarter. 34.56% of the stock is currently owned by institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.